Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer.
APAF1
hypoxia
miR-23a-3p
miRNA
ovarian cancer
platinum response
prognostic marker
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
04 Jul 2021
04 Jul 2021
Historique:
received:
15
04
2021
accepted:
25
06
2021
entrez:
20
7
2021
pubmed:
21
7
2021
medline:
21
7
2021
Statut:
epublish
Résumé
The onset of chemo-resistant recurrence represents the principal cause of high-grade serous ovarian carcinoma (HGSOC) death. HGSOC masses are characterized by a hypoxic microenvironment, which contributes to the development of this chemo-resistant phenotype. Hypoxia regulated-miRNAs (HRMs) represent a molecular response of cancer cells to hypoxia and are involved in tumor progression. We investigated the expression of HRMs using miRNA expression data from a total of 273 advanced-stage HGSOC samples. The miRNAs associated with chemoresistance and survival were validated by RT-qPCR and target prediction, and comparative pathway analysis was conducted for target gene identification. Analysis of miRNA expression profiles indicated miR-23a-3p and miR-181c-5p over-expression as associated with chemoresistance and poor PFS. RT-qPCR data confirmed upregulation of miR-23a-3p in tumors from chemoresistant HGSOC patients and its significant association with shorter PFS. In silico miR-23a-3p target prediction and comparative pathway analysis identified platinum drug resistance as the pathway with the highest number of miR-23a-3p target genes. Among them, APAF-1 emerged as the most promising, being downregulated in platinum-resistant patients and in HGSOC chemo-resistant cells. These results highlight miR-23a-3p as a potential biomarker for HGSOC platinum response and prognosis and the miR23a-3p/APAF1 axis as a possible target to overcome platinum-resistance.
Identifiants
pubmed: 34283087
pii: cancers13133358
doi: 10.3390/cancers13133358
pmc: PMC8268862
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondazione Cariplo
ID : 2013-0815
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG 21837
Références
Semin Oncol. 2006 Apr;33(2 Suppl 6):S12-6
pubmed: 16716798
PLoS One. 2018 Nov 26;13(11):e0207319
pubmed: 30475821
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
PLoS One. 2013;8(2):e56647
pubmed: 23437196
Mol Cell Biol. 2007 Mar;27(5):1859-67
pubmed: 17194750
Oncotarget. 2015 May 10;6(13):11342-56
pubmed: 25839163
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
Oncotarget. 2016 Mar 22;7(12):13464-78
pubmed: 26859576
BMC Bioinformatics. 2012 Jan 31;13:20
pubmed: 22292714
Clin Transl Oncol. 2009 Sep;11(9):564-71
pubmed: 19775995
J Clin Oncol. 2012 Jun 10;30(17):2039-45
pubmed: 22529265
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5331-6
pubmed: 24706848
BMC Cancer. 2017 May 25;17(1):366
pubmed: 28545541
Cancers (Basel). 2018 Dec 20;11(1):
pubmed: 30577536
J Cell Mol Med. 2016 Dec;20(12):2341-2348
pubmed: 27419385
Oncogenesis. 2016 Jan 25;5:e190
pubmed: 26807645
Clin Chem. 2015 Nov;61(11):1333-42
pubmed: 26408530
Cancer Biol Ther. 2019;20(6):897-911
pubmed: 30862230
Nucleic Acids Res. 2018 Jan 4;46(D1):D239-D245
pubmed: 29156006
Cancer Metastasis Rev. 2015 Mar;34(1):19-40
pubmed: 25544368
Nucleic Acids Res. 2012 Jan;40(2):761-74
pubmed: 21917858
J Pharmacokinet Biopharm. 1984 Feb;12(1):83-91
pubmed: 6747820
Cancer Res. 2011 Jul 1;71(13):4720-31
pubmed: 21555366
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Commun. 2016 Mar 29;7:11150
pubmed: 27021436
Nat Rev Cancer. 2012 Oct;12(10):699-709
pubmed: 23001349
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Oncogene. 2016 Aug 18;35(33):4312-20
pubmed: 26725326
Br J Cancer. 2016 Sep 6;115(6):731-40
pubmed: 27537390
Oncol Lett. 2018 Jul;16(1):262-266
pubmed: 29928410
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Int J Cancer. 2013 Aug 15;133(4):867-78
pubmed: 23389731
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
J Cell Mol Med. 2011 Jul;15(7):1593-602
pubmed: 20716115
Int J Clin Exp Med. 2015 Aug 15;8(8):13329-34
pubmed: 26550261
Cancer Lett. 2017 Mar 1;388:320-327
pubmed: 28017893
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W169-73
pubmed: 23680784
Int J Mol Sci. 2014 Jul 02;15(7):11713-29
pubmed: 24992592
J Clin Oncol. 2019 Sep 10;37(26):2317-2328
pubmed: 31216226
Cancer Biol Ther. 2008 Feb;7(2):255-64
pubmed: 18059191
Int J Cancer. 2020 Jul 15;147(2):565-574
pubmed: 32096871
Biochem Biophys Res Commun. 2018 Mar 4;497(2):513-520
pubmed: 29452092
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W186-92
pubmed: 17526521
Elife. 2015 Aug 12;4:
pubmed: 26267216